A large trial has shown that a vaccine can protect against HIV acquisition. The task now is to figure out how to build on this initial success.
In late September, the U.S. Military HIV Research Program announced that, for the first time ever, an investigational vaccine regimen showed efficacy in preventing HIV acquisition (JW AIDS Clin Care Sep 28 2009). Now, the full results of this community-based trial have been presented at the AIDS Vaccine Conference and published in the New England Journal of Medicine.
As previously described, the trial involved 16,402 healthy volunteers in Thailand (age range, 18–30) who were randomized 1:1 to receive placebo or a prime-boost regimen that involved two vaccines (ALVAC-HIV and AIDSVAX B/E) designed to protect against clades B and E. The trial had two primary endpoints: a decrease in HIV acquisition, and, among those who became infected during t…
Reviewing Authors
Frances H. Priddy, MD, MPH
Frances H. Priddy, MD, MPH
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)